AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34620093 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane at concentrations of 0.3, 0.6, and 0.9 MAC
Number of subjects: 40
Study 36151278 — intervention group
Group type: COMPARATOR
Intervention: 1,450 ppm fluoride toothpaste
Number of subjects: 0
Study 36151278 — intervention group
Group type: COMPARATOR
Intervention: 5,000 ppm fluoride toothpaste
Number of subjects: 0
Study 36151278 — intervention group
Group type: COMPARATOR
Intervention: 1,450 ppm fluoride toothpaste + 0.2% sodium fluoride mouth rinse
Number of subjects: 0
Study 32106527 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid PEA (167.5 mg Levagen+ with 832.5 mg maltodextrin)
Number of subjects: 28
Study 32106527 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo (1 g maltodextrin)
Number of subjects: 28
Study 33140673 — intervention group
Group type: EXPERIMENTAL
Intervention: High CPA risk parents
Number of subjects: 165
Study 33140673 — intervention group
Group type: COMPARATOR
Intervention: Low CPA risk parents in high loss condition
Number of subjects: 165
Study 33140673 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of child provocation
Number of subjects: 165
Study 33140673 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive motives
Number of subjects: 165
Study 34775865 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% glucose isotonic electrolyte solution
Number of subjects: 100
Study 34775865 — intervention group
Group type: COMPARATOR
Intervention: Lactated Ringer's solution
Number of subjects: 100
Study 32915904 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated vessel density detection from ultra-widefield fluorescein angiography (UWFFA) images
Number of subjects: 42
Study 32915904 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated vessel density detection from UWFFA images
Number of subjects: 42
Study 35165795 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-positive women
Number of subjects: 700
Study 35165795 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-negative women
Number of subjects: 700
Study 34398237 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin therapy for 48 weeks
Number of subjects: 0
Study 34398237 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35475874 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 32624569 — intervention group
Group type: EXPERIMENTAL
Intervention: 150mg L-DOPA
Number of subjects: 27
Study 32624569 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg haloperidol
Number of subjects: 27
Study 32624569 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 27
Study 35173278 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined training (CT)
Number of subjects: 34
Study 32701397 — intervention group
Group type: EXPERIMENTAL
Intervention: MUST-Plus (machine learning classifier)
Number of subjects: 0
Study 32701397 — intervention group
Group type: COMPARATOR
Intervention: MUST (Malnutrition Universal Screening Tool)
Number of subjects: 0
Study 32592439 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 × 3 hour group intervention aiming to prevent symptoms of stress‐related ill health by increasing engagement in proactive behaviors.
Number of subjects: 239
Study 32592439 — intervention group
Group type: COMPARATOR
Intervention: Control intervention (active control condition).
Number of subjects: 239
Study 32592439 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater adherence to the intervention.
Number of subjects: 239
Study 36404406 — intervention group
Group type: EXPERIMENTAL
Intervention: HeartMate 3 (HM3)
Number of subjects: 918
Study 36404406 — intervention group
Group type: COMPARATOR
Intervention: HeartMate II (HMII)
Number of subjects: 918
Study 35918638 — intervention group
Group type: EXPERIMENTAL
Intervention: Erector spinae plane block (ESPB) combined with general anesthesia (group E)
Number of subjects: 60
Study 33475734 — intervention group
Group type: EXPERIMENTAL
Intervention: Etrasimod 2 mg
Number of subjects: 118
Study 32344455 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin 600 mg once daily for one week
Number of subjects: 22
Study 32344455 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 33221594 — intervention group
Group type: EXPERIMENTAL
Intervention: Three stone fire
Number of subjects: 48
Study 33221594 — intervention group
Group type: COMPARATOR
Intervention: Cookstoves (various)
Number of subjects: 48
Study 35016094 — intervention group
Group type: EXPERIMENTAL
Intervention: Vie Scope® laryngoscope
Number of subjects: 90
Study 35016094 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 90
Study 32962936 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex, 4 mg/kg
Number of subjects: 60
Study 32877651 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine 35 mg modified-release twice daily
Number of subjects: 6007
Study 32877651 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6007
Study 35779276 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) intervention
Number of subjects: 1635
Study 35779276 — intervention group
Group type: COMPARATOR
Intervention: Health Education (HE) intervention
Number of subjects: 1635
Study 33761688 — intervention group
Group type: EXPERIMENTAL
Intervention: Qiming granule combined with laser treatment
Number of subjects: 0
Study 33761688 — intervention group
Group type: COMPARATOR
Intervention: Simple laser treatment
Number of subjects: 0
Study 35395778 — intervention group
Group type: EXPERIMENTAL
Intervention: Model-based social media intervention
Number of subjects: 0
Study 35395778 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 0
Study 33596251 — intervention group
Group type: EXPERIMENTAL
Intervention: Health benefits framing
Number of subjects: 900
Study 33596251 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost benefits framing
Number of subjects: 900
Study 33596251 — intervention group
Group type: EXPERIMENTAL
Intervention: Social norms framing
Number of subjects: 900
Study 33596251 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall swaps offered
Number of subjects: 900
Study 33596251 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall energy change per product
Number of subjects: 900
Study 33596251 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall energy change per shopping basket
Number of subjects: 900
Study 32551819 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialectical behaviour therapy
Number of subjects: 162
Study 32551819 — intervention group
Group type: COMPARATOR
Intervention: Conversational model
Number of subjects: 162
Study 35259535 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 200/300 mg
Number of subjects: 0
Study 35259535 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32909336 — intervention group
Group type: EXPERIMENTAL
Intervention: Respirator liner made of polyurethane foam designed to redistribute pressure across the face.
Number of subjects: 1161
Study 32928196 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive tutorials for head CT
Number of subjects: 91
Study 32928196 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive tutorials for chest CT
Number of subjects: 91
Study 32928196 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive tutorials
Number of subjects: 91
Study 32928196 — intervention group
Group type: COMPARATOR
Intervention: Web-based resources
Number of subjects: 91
Study 34153006 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal 2‐chloroprocaine 3% 50 mg with fentanyl 15 µg
Number of subjects: 43
Study 34153006 — intervention group
Group type: COMPARATOR
Intervention: Hyperbaric bupivacaine 0.75% 9 mg with fentanyl 15 µg
Number of subjects: 43
Study 34489189 — intervention group
Group type: EXPERIMENTAL
Intervention: Health coaching (PuSHCon)
Number of subjects: 87
Study 34489189 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 87
Study 33975569 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy School Start Plus (HSSP) programme, which includes classroom activities and home assignments for children.
Number of subjects: 36
Study 34185138 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized dose regimen based on BMI
Number of subjects: 78
Study 32299763 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS (2 mA, 20 min, 2 sessions/day for five weekdays)
Number of subjects: 60
Study 32299763 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 60
Study 34217851 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-interval dinoprostone (3 mg vaginally 12 hours before OH)
Number of subjects: 180
Study 34217851 — intervention group
Group type: COMPARATOR
Intervention: Short-interval dinoprostone (3 mg vaginally 3 hours before OH)
Number of subjects: 180
Study 34217851 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-interval dinoprostone
Number of subjects: 180
Study 34217851 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 180
Study 34655175 — intervention group
Group type: EXPERIMENTAL
Intervention: FL followed by PTX (FL/PTX)
Number of subjects: 94
Study 34655175 — intervention group
Group type: COMPARATOR
Intervention: FL followed by best supportive care (FL/BSC)
Number of subjects: 94
Study 34655175 — intervention group
Group type: COMPARATOR
Intervention: FLTAX (5‐fluorouracil/leucovorin and paclitaxel)
Number of subjects: 94
Study 34655175 — intervention group
Group type: EXPERIMENTAL
Intervention: FLTAX
Number of subjects: 94
Study 33465041 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin Failure Clinical Indicator Scale (SFCIS)
Number of subjects: 52
Study 33465041 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum albumin level < 3.5 mg/dL
Number of subjects: 52
Study 33465041 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired blood flow
Number of subjects: 52
Study 33465041 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of sepsis/multiorgan dysfunction syndrome
Number of subjects: 52
Study 33465041 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressor/inotrope use
Number of subjects: 52
Study 33465041 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation
Number of subjects: 52
Study 33611722 — intervention group
Group type: EXPERIMENTAL
Intervention: Head CTs
Number of subjects: 100
Study 33611722 — intervention group
Group type: EXPERIMENTAL
Intervention: Shunt series x-rays
Number of subjects: 100
Study 33611722 — intervention group
Group type: EXPERIMENTAL
Intervention: MRIs
Number of subjects: 100
Study 33611722 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation exposure
Number of subjects: 100
Study 35050548 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan oral solution 160 mg
Number of subjects: 82
Study 35050548 — intervention group
Group type: COMPARATOR
Intervention: Valsartan suspension formulation
Number of subjects: 82
Study 34193267 — intervention group
Group type: EXPERIMENTAL
Intervention: FIFA 11 + shoulder programme (11 + S) performed as warm up protocol, three times per week
Number of subjects: 32
Study 34193267 — intervention group
Group type: COMPARATOR
Intervention: Routine warm up protocol
Number of subjects: 32
Study 32713290 — intervention group
Group type: EXPERIMENTAL
Intervention: PRECIOUS only (app + biofeedback + follow‐ups)
Number of subjects: 31
Study 32713290 — intervention group
Group type: EXPERIMENTAL
Intervention: PRECIOUS + MI (app + biofeedback + motivational interviewing follow‐ups)
Number of subjects: 31
Study 32713290 — intervention group
Group type: COMPARATOR
Intervention: Control group (TAU + biofeedback + follow‐ups)
Number of subjects: 31
Study 33529502 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser (G1; n = 12)
Number of subjects: 25
Study 33529502 — intervention group
Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG laser (G2; n = 13)
Number of subjects: 25
Study 36269670 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive self-disclosure posts
Number of subjects: 382
Study 36269670 — intervention group
Group type: COMPARATOR
Intervention: Negative self-disclosure posts
Number of subjects: 382
Study 33357057 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening
Number of subjects: 0
Study 33357057 — intervention group
Group type: EXPERIMENTAL
Intervention: EaveTubes
Number of subjects: 0
Study 34753859 — intervention group
Group type: EXPERIMENTAL
Intervention: Low carbohydrate-to-protein ratio intervention
Number of subjects: 61
Study 34753859 — intervention group
Group type: EXPERIMENTAL
Intervention: High carbohydrate-to-protein ratio intervention
Number of subjects: 61
Study 34753859 — intervention group
Group type: COMPARATOR
Intervention: Usual dietary habits
Number of subjects: 61
Study 34903585 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral morphine
Number of subjects: 0
Study 34903585 — intervention group
Group type: COMPARATOR
Intervention: Transmucosal diamorphine
Number of subjects: 0
Study 35984425 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide (GLP-1RA)
Number of subjects: 148
Study 35984425 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin (SGLT2i)
Number of subjects: 148
Study 35984425 — intervention group
Group type: COMPARATOR
Intervention: Sitagliptin (DPP-4 inhibitor)
Number of subjects: 148
Study 35984425 — intervention group
Group type: COMPARATOR
Intervention: Dietary interventions
Number of subjects: 148
Study 34114882 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic correlation analyses, look-up analyses, and Mendelian randomization (MR) studies
Number of subjects: 0
Study 34114882 — intervention group
Group type: EXPERIMENTAL
Intervention: Mendelian randomization (MR) studies
Number of subjects: 0
Study 32971991 — intervention group
Group type: EXPERIMENTAL
Intervention: Kiwifruit (2 SunGold™ kiwifruit/day)
Number of subjects: 167
Study 32971991 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (250 mg tablet/day)
Number of subjects: 167
Study 32971991 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1 tablet/day)
Number of subjects: 167
Study 34260297 — intervention group
Group type: EXPERIMENTAL
Intervention: NACRT (Neoadjuvant chemoradiotherapy) combined with postoperative adjuvant XELOX chemotherapy
Number of subjects: 60
Study 34260297 — intervention group
Group type: COMPARATOR
Intervention: ACT (Postoperative adjuvant chemotherapy with XELOX)
Number of subjects: 60
Study 32144924 — intervention group
Group type: EXPERIMENTAL
Intervention: Single acupoint Zusanli (ST36)
Number of subjects: 70
Study 32144924 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-acupoints Zusanli (ST36), Shangjuxu (ST37) and Neiguan (PC6)
Number of subjects: 70
Study 32144924 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine basic treatments)
Number of subjects: 70
Study 35998283 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 40
Study 35998283 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 35211483 — intervention group
Group type: EXPERIMENTAL
Intervention: TeleClinical Care (TCC)
Number of subjects: 164
Study 35211483 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 164
Study 35133871 — intervention group
Group type: EXPERIMENTAL
Intervention: Copanlisib (60 mg intravenous) once weekly on days 1, 8, and 15 in 28-day cycles until progression or toxicity
Number of subjects: 25
Study 32757247 — intervention group
Group type: EXPERIMENTAL
Intervention: ITR-containing product for three weeks
Number of subjects: 30
Study 32757247 — intervention group
Group type: COMPARATOR
Intervention: Control (no ITR treatment)
Number of subjects: 30
Study 36226865 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Number of subjects: 0
Study 36226865 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32745227 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenous bone graft (ABG)
Number of subjects: 153
Study 32745227 — intervention group
Group type: EXPERIMENTAL
Intervention: Demineralized bone matrix (DBM)
Number of subjects: 153
Study 32745227 — intervention group
Group type: EXPERIMENTAL
Intervention: No graft (NG)
Number of subjects: 153
Study 616588608 — intervention group
Group type: EXPERIMENTAL
Intervention: Text message reminders (texting group)
Number of subjects: 6989
Study 616588608 — intervention group
Group type: COMPARATOR
Intervention: Traditional phone call reminder (nontexting group)
Number of subjects: 6989
Study 35644335 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrieval of IVC filters
Number of subjects: 100
Study 34090765 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% urea cream
Number of subjects: 60
Study 34090765 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 60
Study 34090765 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% urea cream
Number of subjects: 60
Study 32026432 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance therapy with rituximab
Number of subjects: 66
Study 32026432 — intervention group
Group type: COMPARATOR
Intervention: No maintenance therapy (observation with serial MRI scans)
Number of subjects: 66
Study 35397950 — intervention group
Group type: EXPERIMENTAL
Intervention: More intensive blood pressure control strategy
Number of subjects: 60870
Study 33882601 — intervention group
Group type: EXPERIMENTAL
Intervention: TCC‐Cardiac app
Number of subjects: 164
Study 33882601 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 164
Study 33882601 — intervention group
Group type: EXPERIMENTAL
Intervention: TCC‐COVID app
Number of subjects: 164
Study 32991492 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal use of beta-blockers during the first trimester of pregnancy
Number of subjects: 106
Study 32991492 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal use of progestogens during the first trimester of pregnancy
Number of subjects: 106
Study 32991492 — intervention group
Group type: EXPERIMENTAL
Intervention: Young maternal age (less than 25 years)
Number of subjects: 106
Study 32991492 — intervention group
Group type: EXPERIMENTAL
Intervention: Primiparity
Number of subjects: 106
Study 34487087 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese children
Number of subjects: 91
Study 35647823 — intervention group
Group type: EXPERIMENTAL
Intervention: Dezocine combined with dexmedetomidine
Number of subjects: 80
Study 35647823 — intervention group
Group type: COMPARATOR
Intervention: Control group (Dezocine only)
Number of subjects: 80
Study 33308038 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium animalis subsp. lactis MN-Gup yogurt
Number of subjects: 0
Study 33308038 — intervention group
Group type: COMPARATOR
Intervention: Placebo yogurt
Number of subjects: 0
Study 32389105 — intervention group
Group type: EXPERIMENTAL
Intervention: Liberal blood glucose control (target 10.0-14.0 mmol/L)
Number of subjects: 450
Study 32389105 — intervention group
Group type: COMPARATOR
Intervention: Usual care (target 6.0-10.0 mmol/L)
Number of subjects: 450
Study 35085524 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump coronary artery bypass graft surgery
Number of subjects: 768
Study 35085524 — intervention group
Group type: COMPARATOR
Intervention: On-pump coronary artery bypass graft surgery
Number of subjects: 768
Study 33731111 — intervention group
Group type: EXPERIMENTAL
Intervention: Attractive Targeted Sugar Baits (ATSBs)
Number of subjects: 0
Study 35173379 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) training for 5 weeks, twice a week, 30 min sessions
Number of subjects: 96
Study 35173379 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vibration during training)
Number of subjects: 96
Study 33689853 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep Learning-Based Computed Tomography Perfusion Mapping (DL-CTPM)
Number of subjects: 146
Study 35509000 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress condition (Trier Social Stress Test for Groups)
Number of subjects: 70
Study 35509000 — intervention group
Group type: COMPARATOR
Intervention: Control condition (Trier Social Stress Test for Groups)
Number of subjects: 70
Study 34563227 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician-directed nudges
Number of subjects: 5500
Study 34563227 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-directed nudges
Number of subjects: 5500
Study 34563227 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of clinician and patient-directed nudges
Number of subjects: 5500
Study 34563227 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 5500
Study 34953526 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad5-nCoV vaccine (0.5 mL dose of 5 × 10^10 viral particle/mL)
Number of subjects: 36717
Study 34953526 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.5 mL)
Number of subjects: 36717
Study 34953526 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad5-nCoV vaccine
Number of subjects: 36717
Study 34953526 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36717
Study 36383249 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine containing multi-ingredient pre-workout supplement (SUPP)
Number of subjects: 10
Study 36383249 — intervention group
Group type: COMPARATOR
Intervention: Color and flavor matched placebo (PL)
Number of subjects: 10
Study 35338753 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute Intermittent Hypoxia (AIH) - 30 minutes of alternating 1-minute hypoxia (FiO2 ≈ 0.09) and 1-minute normoxia
Number of subjects: 14
Study 35338753 — intervention group
Group type: COMPARATOR
Intervention: Sham intervention (normoxia, FiO2 ≈ 0.21)
Number of subjects: 14
Study 34036721 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumour-treating fields (TTFields)
Number of subjects: 0
Study 34036721 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care therapies (radiotherapy and temozolomide chemotherapy)
Number of subjects: 0
Study 34339267 — intervention group
Group type: COMPARATOR
Intervention: SPR206 (10 mg to 400 mg single doses; 25 mg to 150 mg every 8 hours for 7 days; 100 mg every 8 hours for 14 days)
Number of subjects: 94
Study 34339267 — intervention group
Group type: COMPARATOR
Intervention: SPR206 (100 mg every 8 hours for 14 days)
Number of subjects: 94
Study 34339267 — intervention group
Group type: COMPARATOR
Intervention: SPR206 (various doses)
Number of subjects: 94
Study 34444802 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (6-month program including six group seminars and eight telephone consultations)
Number of subjects: 404
Study 34444802 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 404